AstraZeneca and Max Planck Institute announce research agreement to create satellite chemistry unit for cardiovascular and metabolic diseases
08 July 2014 AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.The new collaboration will see AstraZeneca scientists working side-by-side with researchers from the Max Planck Institute of Molecular Physiology, in the Department of Chemical Biology, led by Professor Herbert Waldmann. The satellite unit will focus on novel chemistry and